Drugs in Dev.
Musculoskeletal
Phase III
Canada 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Abaloparatide
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Endo International
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
Details : Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities relat...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
January 05, 2021
Lead Product(s) : Abaloparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Endo International
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Palovarotene is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myositis Ossificans.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2017
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Iron
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Capital Health, Canada | Dalhousie University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Oral Iron on Postoperative Fatigue Upon Coronary Artery Bypass Graft Patients
Details : Iron is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fatigue.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 31, 2013
Lead Product(s) : Iron
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Capital Health, Canada | Dalhousie University
Deal Size : Inapplicable
Deal Type : Inapplicable
